Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof

ABSTRACT

The present invention provides new methods for the synthesis of the therapeutic dinucleotide, P1,P4-di(uridine 5&#39;-tetraphosphate), and demonstrates applicability to the production of large quantities. The methods of the present invention substantially reduce the time period required to synthesize diuridine tetraphosphate, preferably to three days or less. The novel tetrammonium and tetrasodium salts of P1,P4-di(uridine 5&#39;-tetraphosphate) (Formula I) prepared by these methods are stable, soluble, nontoxic, and easy to handle during manufacture,wherein:X is Na, NH4 or H, provided that all X groups are not H.

This application claims priority to U.S. Provisional Application60/054,147 filed Jul. 25, 1997; which is continuation-in-part of U.S.application Ser. No. 08/675,620, filed Jul. 3, 1996, U.S. Pat. No.5,789,391.

TECHNICAL FIELD

This invention relates to methods for the production of therapeuticdinucleotides including novel salts thereof. More specifically, itrelates to methods for synthesis of P¹,P⁴-di(uridine 5′-tetraphosphate),i.e., diuridine tetraphosphate (U₂P₄) which have advantages over priorart methods of manufacture.

BACKGROUND OF THE INVENTION

P¹,P⁴-Di(uridine 5′-tetraphosphate) is a dinucleotide of the followingstructure:

wherein:

X is Na, NH₄ or H, provided that all X groups are not H.

The free acid of P¹,P⁴-di(uridine 5′)-tetraphosphate, where X ishydrogen, has been previously described as uridine 5′-(pentahydrogentetraphosphate), P′″→5′-ester with uridine (CAS Registry Number:59985-21-6; C. Vallejo et al., Biochimica et Biophysica Acta 438, 305(1976) and H. Coste et al., J. Biol. Chem. 262, 12096 (1987)).

Different methods have been described for the synthesis of purinedinucleotides such as diadenosine tetraphosphate (A₂P₄) (E. Rappaport etal, Proc. Natl. Acad. Sci, 78, 838, (1981); A. Guranowski et al,Biochemistry, 27, 2959, (1988); C. Lobaton et al, Eur. J. Biochem., 50,495, 1975; K. Ng and L. Orgel, Nucl. Acid Res., 15, 3573, (1987)).However, this has not been true for U₂P₄ which is a pyrimidinenucleotide. Although purine nucleotides and pyrimidine nucleotidesappear to be analogous, the methods used for purine nucleotide synthesisdo not necessarily work for pyrimidines such as uridine.

Diuridine tetraphosphate has been shown to have beneficial properties inthe treatment of various diseases, such as chronic obstructive pulmonarydisease (COPD). For example, they have been demonstrated to facilitatethe clearance of mucous secretions from the lungs of a subject such as amammal including humans in need of treatment for various reasons,including cystic fibrosis, chronic bronchitis, asthma, bronchiectasis,post-operative mucous retention, pneumonia, primary ciliary dyskinesia(M. J. Stutts, III, et al, U.S. Pat. No. 5,635,160; PCT InternationalPublication WO 96/40059) and the prevention and treatment of pneumoniain immobilized patients (K. M. Jacobus and H. J. Leighton, U.S. Pat. No.5,763,447). Further therapeutic uses include treatment of sinusitis (PCTInternational Publication WO 98/03177), otitis media (PCT InternationalPublication WO 97/29756), dry eye, retinal detachment, nasolacrimal ductobstruction, the treatment of female infertility and irritation due tovaginal dryness via increased mucus secretions and hydration of theepithelial surface, and enhancing the performance of athletes.

U₂P₄ also has utility as a veterinary product in mammals such as, butnot limited to, dogs, cats and horses.

Prior art methodology describes only one protocol for the production ofdiuridine tetraphosphate. This method is very time consuming, lastingover five days and producing only small amounts of diuridinetetraphosphate (C. Vallejo et al., Biochimica et Biophysica Acta 438,305 (1976), Sillero et al., Eur J Biochem 76, 332 (1972)). According tothis technique, diuridine tetraphosphate was synthesized through areaction of uridine 5′-monophosphomorpholidate (0.54 mmol) with thetriethylamine salt of pyrophosphoric acid (0.35 mmol) in a medium ofanhydrous pyridine (10 ml). After 5 days at 30° C., pyridine was removedfrom the reaction mixture by evaporation, and the residue resuspended inglass-distilled water (8 mL), the suspension applied to a DEAE-cellulosecolumn (37.5×2.6 cm) and fractionated with 3.2 L of a linear gradient(0.06-0.25 M) of ammonium bicarbonate, pH 8.6. The peak eluting between0.17-0.19 M ammonium bicarbonate was partially characterized as U₂P₄ bythe following criteria: insensitivity to alkaline phosphatase,phosphorus to base ratio and analysis of the products of hydrolysis(UTP+UMP), after treatment with phosphodiesterase I, by electrophoresisin citrate buffer, pH 5.0. No yield or spectroscopic data were given.Thus, the prior art procedure for the synthesis of diuridinetetraphosphate is lengthy and produced only small amounts of onlypartially characterized diuridine tetraphosphate. The present inventionfocuses on methods to produce this medically useful compound which maybe more efficiently and conveniently carried out, and which may beapplied to the large-scale production of diuridine tetraphosphate andsalts thereof.

SUMMARY OF THE INVENTION

The present invention provides new methods for the synthesis of thetherapeutic dinucleotide, P¹,P⁴-di(uridine 5′-tetraphosphate) (FormulaI), and demonstrates applicability to the production of largequantities. The methods of the present invention substantially reducethe time required to synthesize diuridine tetraphosphate, preferably tothree days or less. The novel ammonium and sodium salts ofP¹,P⁴-di(uridine 5′-tetraphosphate) prepared by these methods arestable, soluble, nontoxic, and easy to handle during manufacture. Thetetraammonium salt is preferred; the tetrasodium salt is most preferred.

wherein:

X is Na, NH₄ or H, provided that all X groups are not H.

The method of synthesizing compounds of Formula I, and pharmaceuticallyacceptable salts thereof, is carried out generally by the followingsteps: 1) dissolving uridine or uridine nucleotide compounds of FormulasIIa-d in a polar, aprotic organic solvent and a hydrophobic amine; 2)phosphorylating with a phosphorylating agent of Formulas IVa-b and/oractivating with an activating agent of Formulas IIIa-c; and 3) purifyingby ion exchange chromatography.

Another aspect of the present invention are methods of treating variousdisease states, including, but not limited to: chronic obstructivepulmonary diseases, sinusitis, otitis media, nasolacrimal ductobstruction, dry eye disease, retinal detachment, pneumonia, and femaleinfertility or irritation caused by vaginal dryness.

Another aspect of the present invention is a pharmaceutical compositioncomprising a compound of Formula I together with a pharmaceuticallyacceptable carrier.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides new methods for the synthesis of thetherapeutic dinucleotide, P¹,P⁴-di(uridine 5′-tetraphosphate), anddemonstrates applicability to the production of large quantities. Themethods of the present invention substantially reduce the time periodrequired to synthesize P¹,P⁴-di(uridine 5′-tetraphosphate), preferablyto three days or less. The ammonium and sodium salts of P¹,P⁴-di(uridine5′-tetraphosphate) (Formula I) prepared by these methods are stable,soluble, nontoxic, and easy to handle during manufacture.

The present invention further provides compounds of Formula I:

wherein:

X is Na, NH₄ or H, provided that all X groups are not H.

The sodium and ammonium salts of P¹,P⁴-di(uridine 5′-tetraphosphate)have many advantages. The sodium and ammonium salts provide goodlong-term stability profiles compared to those of divalent cations (e.g.Ca²⁺, Mg²⁺, Mn²⁺) which catalyze hydrolysis of phosphate esters. Thetetrasodium salt of P¹,P⁴-di(uridine 5′-tetraphosphate) isnon-irritating to the lung and eyes. Other cations may be irritating tothe lungs, eyes, and other mucosal epithelia, or are otherwise not welltolerated by the human body. These inorganic sodium and ammonium saltsimpart excellent water solubility compared to hydrophobic amine saltssuch as tri- and tetrabutylammonium, and similar salts. High watersolubility is an important advantage for flexibility in pharmaceuticalformulations of varying concentration. The tetraammonium and tetrasodiumsalts of P¹,P⁴-di(uridine 5′-tetraphosphate) are also advantageous inthat they are readily purified by aqueous ion chromatography in which noorganic solvents are used. In addition, these salts are easily handledas fluffy, white solids, compared to an oil or gum as with some aminesalts.

The tetrasodium salt is preferred.

The compounds of Formula I may be used to facilitate the clearance ofmucous secretions from the lungs of a subject such as a mammal includinghumans in need of treatment for various reasons, including cysticfibrosis, chronic bronchitis, asthma, bronchiectasis, post-operativemucous retention, pneumonia, primary ciliary dyskinesia (M. J. Stutts,III, et al, U.S. Pat. No. 5,635,160; PCT International Publication WO96/40059) and the prevention and treatment of pneumonia in immobilizedpatients (K. M. Jacobus and H. J. Leighton, U.S. Pat. No. 5,763,447).Further therapeutic uses include treatment of sinusitis (PCTInternational Publication WO 98/03177), otitis media (PCT InternationalPublication WO 97/29756), dry eye, retinal detachment, nasolacrimal ductobstruction, the treatment of female infertility and irritation due tovaginal dryness via increased mucus secretions and hydration of theepithelial surface, and enhancing the performance of athletes.

The compounds of Formula I may be administered orally, topically,parenterally, by inhalation or spray, intra-operatively, rectally, orvaginally in dosage unit formulations containing conventional non-toxicpharmaceutically acceptable carriers, adjuvants and vehicles. The termtopically as used herein includes patches, gels, creams, ointments,suppositiories, pessaries, or nose, ear or eye drops. The termparenteral as used herein includes subcutaneous injections, intravenous,intramuscular, intrasternal injection or infusion techniques. Inaddition, there is provided a pharmaceutical formulation comprising acompound of general Formula I and a pharmaceutically acceptable carrier.One or more compounds of general Formula I may be present in associationwith one or more non-toxic pharmaceutically acceptable carriers ordiluents or adjuvants and, if desired, other active ingredients. Onesuch carrier would be sugars, where the compounds may be intimatelyincorporated in the matrix through glassification or simply admixed withthe carrier (e.g., lactose, sucrose, trehalose, mannitol) or otheracceptable excipients for lung or airway delivery.

One or more compounds of general Formula I may be administeredseparately or together, or separately or together with: mucolytics suchas DNAse (Pulmozyme®) or acetylcysteine, antibiotics, including but notlimited to inhaled Tobramycin®; non-steroidal anti-inflammatories,antivirals, vaccines, decongestants and corticosteroids.

The pharmaceutical compositions containing compounds of general FormulaI may be in a form suitable for oral use, for example, as tablets,caplets, lozenges, aqueous or oily suspensions, dispersible powders orgranules, emulsion, hard or soft capsules, or syrups or elixirs.Compositions intended for oral use may be prepared according to anymethod known to the art for the manufacture of pharmaceuticalcompositions and such compositions may contain one or more agentsselected from the group consisting of sweetening agents, flavoringagents, coloring agents and preserving agents in order to providepharmaceutically elegant and palatable preparations. Tablets contain theactive ingredient in admixture with non-toxic pharmaceuticallyacceptable excipients which are suitable for the manufacture of tablets.These excipients may be, for example, inert diluents, such as calciumcarbonate, sodium carbonate, lactose, calcium phosphate or sodiumphosphate; granulating and disintegrating agents, for example, cornstarch, or alginic acid; binding agents, for example, starch, gelatin oracacia; and lubricating agents, for example magnesium stearate, stearicacid or talc. The tablets may be uncoated or they may be coated by knowntechniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate may be employed.

Formulations for oral use may also be presented as hard gelatin capsuleswherein the active ingredient is mixed with an inert solid diluent, forexample, calcium carbonate, calcium phosphate or kaolin, or as softgelatin capsules wherein the active ingredients is mixed with water oran oil medium, for example, peanut oil, liquid paraffin or olive oil.

Aqueous suspensions contain the active materials in admixture withexcipients suitable for the manufacture of aqueous suspensions. Suchexcipients are suspending agents, for example: sodiumcarboxymethylcellulose, methylcellulose and sodium alginate. Dispersingor wetting agents may be a naturally-occurring phosphatide orcondensation products of an allylene oxide with fatty acids, orcondensation products of ethylene oxide with long chain aliphaticalcohols, or condensation products of ethylene oxide with partial estersfrom fatty acids and a hexitol, or condensation products of ethyleneoxide with partial esters derived from fatty acids and hexitolanhydrides. Those skilled in the art will recognize the many specificexcipients and wetting agents encompassed by the general descriptionabove. The aqueous suspensions may also contain one or morepreservatives, for example, ethyl, or n-propyl p-hydroxybenzoate, one ormore coloring agents, one or more flavoring agents, and one or moresweetening agents, such as sucrose or saccharin.

Dispersible powders and granules suitable for preparation of an aqueoussuspension by the addition of water provide the active ingredients inadmixture with a dispersing or wetting agent, suspending agent and oneor more preservatives. Suitable dispersing or wetting agents andsuspending agents are exemplified by those already mentioned above.Additional excipients, for example, sweetening, flavoring, and coloringagents, may also be present.

Compounds of Formula I may be administered parenterally in a sterilemedium. The drug, depending on the vehicle and concentration used, caneither be suspended or dissolved in the vehicle. Advantageously,adjuvants such as local anaesthetics, preservatives and buffering agentscan be dissolved in the vehicle. The sterile injectable preparation maybe a sterile injectable solution or suspension in a non-toxic parentallyacceptable diluent or solvent. Among the acceptable vehicles andsolvents that may be employed are sterile water, saline solution, orRinger's solution. The compounds of general Formula I may also beadministered in the form of suppositories for ear, rectal or vaginaladministration of the drug. These compositions can be prepared by mixingthe drug with a suitable non-irritating excipient which is solid atordinary temperatures but liquid at the body temperature and willtherefore melt to release the drug. Such materials are cocoa butter andpolyethylene glycols.

Solutions of compounds of Formula I may be administered byintra-operative installation at any site in the body.

Single dosage levels of the order of from about 1 to about 400 mg,preferably in the range of 10 to 300 mg, and most preferably in therange of 25 to 250 mg, are useful in the treatment of theabove-indicated respiratory conditions. Single dosage levels of theorder of from about 0.0005 to about 5 mg, preferably in the range of0.001 to 3 mg and most preferably in the range of 0.025 to 1 mg, areuseful in the treatment of the above-indicated ophthalmic conditions.The amount of active ingredient that may be combined with the carriermaterials to produce a single dosage form will vary depending upon thehost treated and the particular mode of administration. It will beunderstood, however, that the specific dose level for any particularpatient will depend upon a variety of factors including the activity ofthe specific compound employed, the age, body weight, general health,sex, diet, time of administration, route of administration, and rate ofexcretion, drug combination and the severity of the particular diseaseundergoing therapy.

The synthetic methods described below encompass several syntheticstrategies for producing P¹,P⁴-di(uridine 5′-tetraphosphate). Generally,all the methods use uridine or uridine nucleotide compounds from FormulaIIa-d as starting materials, which are dissolved in a polar, aproticorganic solvent (e.g. dimethylformamide, dimethylsulfoxide, dioxane,N-methylpyrrolidone, trimethylphosphate) and a hydrophobic amine (e.g.triethylamine, tributylamine, trioctylamine, 2,4,6-collidine,tetrabutylammonium, tri- and tetra-alkyl amines, heterocyclic amines).The product is obtained by phosphorylating with a phosphorylating agentfrom Formula IV (e.g. phosphorus oxychloride, pyrophosphate,pyrophosphorylchloride) or activating a phosphate group with anactivating agent from Formula III (e.g. carbonyldiimidazole, an alky oraryl carbodiimide, an alkyl or aryl phosphochloridate), respectively,with subsequent purification various means well known to those of skillin the art, including, but not limited to, ion chromatography (e.g. DEAESephadex, DEAE cellulose, Dowex 50, anion and cation exchange resins).

The pyrimidine β-D-ribofuranosyl starting materials uridine, uridine5′-monophosphate (UMP), uridine 5′-diphosphate (UDP), and uridine5′-triphosphate (UTP) are shown as free acids in Formulas IIa-d below,respectively. These materials are all commercially available in largequantity in various salt forms.

and salts thereof;

and salts thereof;

and salts thereof.

The activating agents carbodiimide, activated carbonyl, and activatedphosphorus compounds are shown in the general Formulas IIIa-c below,respectively.

wherein R₁ and R₂ are C₁-C₈ alkyl or cycloalkyl, C₁-C₈ optionallysubstituted alkyl or cycloalkyl (e.g. hydroxy and amino groups); aryl oroptionally substituted aryl (e.g. hydroxy and amino groups). Preferredcompounds of Formula IIIa are dicyclohexylcarbodiimide and1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.

wherein X is imidazole, tetrazole, and/or halogen. Preferred compoundsof Formula IIIb are carbonyldiimidazole and carbonylditriazole.

wherein R¹ and R₂ are C₁-C₈ alkyl or cycloalkyl, C₁-C₈ optionallysubstituted alkyl, alkoxy or cycloalkyl (e.g. hydroxy and amino groups);aryl, aryloxy, alkoxy or optionally substituted aryl, aryloxy, or alkoxy(e.g. hydroxy and amino groups) and/or halogen; and X is halogen.Preferred compounds of Formula IIIc are diphenylphosphorochloridate,phenyl phosphorodichloridate, phenylphosphonic dichloride anddiphenylphosphinic chloride.

The mono- and diphosphorylating agents are shown below in the generalformulas IVa-b.

wherein X is halogen. Preferred compound of Formula IVa is phosphorusoxychloride.

wherein X is oxygen, hydroxy, or halogen, and salts thereof. Preferredcompounds of Formula IVb are pyrophosphoryl chloride and pyrophosphate.

Those having skill in the art will recognize that the present inventionis not limited to the following examples and that the steps in thefollowing examples may be varied.

EXAMPLE 1

Method for the Production of Diuridine Tetraphosphate Tetrasodium SaltUsing Uridine 5′-Diphosphate

Uridine 5′-diphosphate disodium salt (Yamasa, Choshi, Japan; 600 grams)was dissolved in deionized water (5.4 L). The solution was passedthrough a Dowex 50Wx4 H⁺ (Dow Chemical) column. The fractions containinguridine 5′-diphosphate were pooled and neutralized with tributylamine(Aldrich, St. Louis; 300 mL). The neutralized fractions wereconcentrated to an oil by using a rotary evaporator at a bathtemperature of 55-60° C. The oil was dissolved in dry dimethylformamide(Aldrich, 3 L) and then dried by concentrating to an oil using a rotaryevaporator (55-60° C. bath temperature). This step was repeated twice.The oil was again dissolved in dimethylformamide (3 L) and1,1-carbonyldiimidazole (Aldrich; 100 g) was added. The solution washeated at 50° C. for 2½ hours. An additional amount of activating agent(33 grams) was added and heating continued for a further 2½ hours. Thesolution was again concentrated to an oil on a rotary evaporator (bathtemperature at 55-60° C.). The resulting oil was dissolved in deionizedwater to a conductivity equal to that of 0.2 M NH₄HCO₃. The solution wasthen loaded into a column of Sephadex DEAE-A25 (Pharmacia, Upsala,Sweden; pre-swollen in 1.0 M NaHCO₃ and washed with 2 column volumes ofdeionized H₂O). The column was eluted with the following solutions inthe following order: 60 L of 0.25 M NH₄HCO₃, 120 L of 0.275M NH₄HCO₃, 40L of 030 M NH₄HCO₃ and 40 L of 0.35 M NH₄HCO₃. The fractions havingsufficient amounts of pure diuridine tetraphosphate were pooled asdetermined by HPLC analysis and concentrated on a rotary evaporator(bath temperature at 55-60° C.). The resulting residue was dissolved indeionized water (1.5 L) and concentrated on a rotary evaporator. Thisstep was repeated 15 times or until excess of bicarbonate buffer wasremoved. The resulting oil was dissolved in a sufficient amount ofdeionized water to form a ca. 10% solution, the solution charged to aDowex 50Wx4 Na⁺ (Dow) column and eluted with deionized water. Thefractions containing U₂P₄ were pooled and concentrated to a ca. 10-15%solution, which was lyophilized to yield U₂P₄ tetrasodium salt as awhite solid (150 g approximately 25% yield based on uridine5′-diphosphate).

Structure Elucidation of P¹,P⁴-di(uridine 5′-tetraphosphate),Tetrasodium Salt

Due to the lack of adequate spectroscopic data of nonadenylateddinucleotides in the literature, a full structure elucidation ofP¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium salt was performed byemploying modern analytical techniques. The molecular weight wasdetermined by mass spectrometry to be 878 [m/z 855,(M-Na⁺)^(−], confirming the molecular formula C) ₁₈H₂₂N₄O₂₃P₄.4Na. Theexact mass measured for C₁₈H₂₂N₄O₂₃P₄.3Na [(M-Na⁺⁾ ⁻: calculated854.9318] was 854.9268. The measured mass differed from the theoreticalmass by 5.0 milimass units (5.9 ppm) for a confidence level of 99.7%.Karl Fisher moisture analysis gave a value of 1.73% H₂O and furtherconfirmation of the molecular formula was obtained from elementalanalysis: calculated for Na=10.70, found 10.81%; C:P ratio calculated1.74, found 1.80, based on the molecular formula:C₁₈H₂₂N₄O₂₃P₄.4.2Na.1.1H₂O (FW=902.4 g/mol). The infrared spectrumshowed a broad signal at 3422 cm⁻¹ and a signal at 1702 cm⁻¹, indicatingthe presence of hydroxyl (O—H stretch) and carbonyl (C=O stretch)functional groups. In addition, a phosphate P═O stretch was observed at1265 cm⁻¹. The UV spectrum in water displayed a λ_(max) of 262 nm with amolar absorptivity (ε) of 17,004. The specific rotation at 25° C. (c=1,H₂O) was determined by polarimetry to be −9.5°.

The NMR spectra are: ¹H NMR (D₂O, TMS) δ 4.11 (m, 2H), 4.14 (m, 1H),4.25 (m, 1H), 4.27 (m, 1H), 5.84 (d, J=8.1 Hz, 1H), 5.86 (d, J=5.4 Hz,1H), 7.81 (d, J=8.1 Hz); ¹³C NMR (D₂O, TMS) δ 65.1 (d, J=5.5 Hz), 69.7,73.5, 83.4 (d, J=9.4 Hz), 88.1, 102.8, 141.5, 152.9, 167.5; ³¹P NMR(D₂O, H₃PO₄ std) δ −22,32 (m), −10.75 (m). The ¹H coupled ³¹P spectrumshowed a broadening of the multiplet at δ −10.75 ppm due to theintroduction of ¹H coupling. This multiplet was therefore confirmed asP_(α). There was no effect of ¹H coupling on the multiplet at −22.23ppm, assigning this by default as P_(β). A Nuclear Overhauser Effect(NOE) was observed for H₆ to the H_(2′)and H_(3′)sugar protons. Becauseit is not possible for H₅ to show an NOE to the sugar protons, H₆ isconfirmed. Additionally, N₁ substitution is confirmed, because nopyrimidine-sugar NOE is possible for an N₃ substituted structure.

Additional 2-dimensional NMR experiments were conducted to verifyconnectivity. HMQC shows connectivity for H₅ to C₅ and H₆ to C₆,confirming C₅ and C₆. COSY and NOE connectivity were observed for H₅ toH₆, verifying H₅. HMBC 3-bond connectivity was observed for: H₆ toC_(1′), C₆ to H_(1′), H_(1′)to C₂, H₆ to C₂. These data thus confirm H₁,C₂ and N₁ substitution. COSY connectivity of H_(1′)to H_(2′)confirmsH_(2′)and HMQC connectivity of H_(1′)to C_(1′)and H_(2′)toC_(2′)confirms C_(1′)and C_(2′). Additionally, HMBC shows 2-bond Jconnectivity from H₅ to C₄, confirming C₄. A ¹³C DEPT spectrum with mult=1.5 shows the carbon at δ 65.1 inverted relative to all other carbons.This observation confirms that C_(5′)is a methylene. The coupling of ³¹Pto carbons at δ 65.1 and 83.4 confirms C_(5′)and C_(4′), becauseC_(4′)is the only coupled methyne. In addition, HMQC shows connectivityfor C_(5′)to H_(5′)and C_(4′)to H_(4′), confirming H_(4′), and H_(5′).An NOE was observed for H_(1′)to H_(4′), H₆ to H_(2′)and H₆ to H_(3′),confirming the β anomer sugar configuration.

In conclusion, P¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium salt wassynthesized on a 150 g scale in 25% yield from commercially availablestarting materials with a total reaction time of 5 hours. The crudeproduct was efficiently purified by ion exchange chromatography and thestructure of the reaction product was unambiguously proven using massspectroscopic, NMR and other analytical techniques.

EXAMPLE 2 Method for the Production of Diuridine TetraphosphateTetraammonium Salt Using Uridine 5′-Monophosphate

Uridine 5′-monophosphate (Sigma, Milwaukee, 3.0 g, 9.26 mmol) wasdissolved in dry DMF (10 mL) and tributylamine (Aldrich, 2 mL). Thesolution was evaporated in vacuo at 40° C. to an oil. The residue wasdissolved in dry DMF (Aldrich, 8 mL) to form a solution.Carbonyldilmidazole (Aldrich, 1.65 g, 10.18 mmol) was added to thissolution. The reaction was heated at 50° C. for one hour. Uridine5′-triphosphate (Yamasa, 5.60 g, 10.18 mmol) prepared as the anhydroustributylammonium salt in DMF (5 mL) and tributylamine (2 mL), asdescribed in Example 3 below, was added to the reaction solution. Themixture was allowed to stir at 50° C. for three days when the solutionwas evaporated in vacuo to an oil, redissolved in water (5 mL) andpurified by column (300×50 mm) chromatography (Sephadex DEAE-A25,40-120μ, Aldrich, pre-swollen in 1.0 M NaHCO₃ and washed with 2 columnvolumes of deionized H₂O (H₂O→0.03 M NH₄HCO₃ gradient). The purefractions were concentrated in vacuo at 35° C., and H₂O added andreevaporated 5 times to obtain diuridine tetraphosphate tetraammoniumsalt as a white solid (2.37 g, 30% yield): 92.11% pure by HPLC with thesame retention time as the standard. In addition, the tetraammonium saltwas analyzed by FABMS to give a mass of [C₁₈H₂₅N₄O₂₃P₄ (M−H⁺)⁻:calculated 788.9860] 788.9857, confirming a parent formula ofC₁₈H₂₆N₄O₂₃P₄ for the free acid].

EXAMPLE 3A Method for the Production of Diuridine Tetraphosphate UsingUridine 5′-Triphosphate (UTP)

A solution of uridine 5′-triphosphate (UTP) trisodium salt (ProBioSint,Varese, Italy; 5.86 g, 0.01 mol) in water (5 mL) was passed through acolumn of BioRad AG-MP 50 (Aldrich) strong cation exchange resin in itstributylamine form (50 mL bed volume) and eluted with distilled water(about 300 mL). To this solution was added tributylamine (Aldrich; 5mL), and the suspension shaken until the pH of the aqueous fraction hadrisen to 8. The layers were separated and the aqueous solutionevaporated to small volume, then lyophilized overnight. The residue wasdissolved in dry dimethylformamide (Aldrich; 20 mL) and the solventevaporated at 0.1 mmHg. The dried tributylamine salt was made up to 100mL with anhydrous acetone to yield a stock solution (0.1 M in UTP).Dicyclohexylcarbodiimide (DCC) (Baker, Phillipsburg; 0.227 g, 1.2 mmol)was added to an aliquot of the foregoing UTP solution (10 mL, 1.0 mmol)and the solution stirred at room temperature for 30 minutes. The mixturewas added to the triethylamine salt of uridine 5′-monophosphate (2.0mmol, prepared by addition of triethylamine (0.5 mL) to a solution ofuridine 5′-monophosphate (UMP) (Sigma; 0.648 g in DMF), and evaporatingto dryness). This suspension was then evaporated to dryness, the residuemade up to 5.0 mL in dry DMF, and set aside at 40° C. for 24 hours. Thereaction mixture was separated by semipreparative ion-exchangechromatography (Hamilton PRP X-100 column), eluting with a gradient of0-1.0 M ammonium bicarbonate, 5 mL/min, 30 minutes. The dinucleotidetetraphosphate eluted between 21 and 23 minutes; the product (76.7%yield based on UTP) was quantitated by comparison of its ultravioletabsorption at λ_(max) 263 nm with that of a standard solution ofP¹,P⁴-di(uridine 5′)-tetraphosphate.

EXAMPLE 3B Method for the Production of Diuridine Tetraphosphate UsingUridine 5′-Triphosphate (UTP) and an Excess of Activating Agent

Conversion of UTP to P¹,P⁴-di(uridine 5′-tetraphosphate) can be enhancedby activation of the tributylamine salt (0.1 mmol) with a large excessof DCC (0.1 g, 0.5 mmol); in this case the deposited dicyclohexylureawas removed by filtration, the reaction mixture extracted with ether (10mL) and the residue dissolved in dry DMF prior to treatment withtributylamine UMP (0.2 mmol). Upon chromatographic separation of thereaction mixture and quantitation by ultraviolet absorption as inExample 3A above, the uridine tetraphosphate product constituted 50.7%of the uridylate species in the mixture, corresponding to a conversionfrom UTP of 95.9%.

EXAMPLE 4A Method for the Production of Diuridine Tetraphosphate UsingUridine 5′-Monophosphate Activated with Carbonyldiimidazole

Uridine 5′-monophosphate (UMP) (0.324 g, 1.0 mmol) was dissolved in amixture of dry DMF (5 mL) and tributylamine (237 μL, 1 mmol) thesolution was evaporated to dryness, then twice more with DMF to yieldthe anhydrous tributylamine salt. The residue was dissolved in DMF (5mL) and carbonyldilmidazole (CDI) (0.81 g, 5 mmol) added. The solutionwas set aside for 3 hours, then methanol 324 μL, 8 mmol) added todestroy the excess of CDI. The solution was set aside for one hour.Tributylamine pyrophosphate (Sigma, 0.228 g, 0.5 mmol) was added and thesuspension stirred under nitrogen at room temperature. After 3 hours thereaction was quenched with water and the mixture subjected to HPLC as inExample 3A above. Yield of P¹,P⁴-di(uridine 5′-tetraphosphate) asquantitated by its absorbance at 263 nm was 9.3%.

EXAMPLE 4B Method for the Production of Diuridine Tetraphosphate UsingUridine 5′-Monophosphate Activated with Diphenyl Phosphochloridate

The anhydrous tributylamine salt of UMP (1.0 mmol), prepared essentiallyas above, was dissolved in a mixture of dry dioxane (5 mL) and DMF (1mL). Diphenyl phosphochloridate (0.3 mL) and tributylamine (0.3 mL) wereadded and the solution set aside at room temperature for 3 hours. Thesolvent was evaporated and the residue shaken with ether (˜10 mL), thenset aside at 4° C. for 30 minutes. The ether was decanted and theresidue was dissolved in a solution of tributylamine pyrophosphate(0.228 g, 0.5 mmol) in DMF (3 mL). The solution was stored undernitrogen at room temperature. After 3 hours the reaction was quenchedwith water and the mixture subjected to HPLC as in Example 3A above.Yield of P¹,P⁴-di(uridine 5′)-tetraphosphate as quantified by itsabsorbance at 263 nm was 9.6%.

EXAMPLE 5 Method for the Production of Diuridine Tetraphosphate UsingUridine, Phosphorus Oxychloride and Pyrophosphate

Uridine (Aldrich, 0.244 g, 1 mmol) was dissolved in trimethyl phosphate(Aldrich, 5 mL) and tributylamine (466 uL, 2 mmol) added. The solutionwas stirred at 0 degrees during the addition of phosphorus oxychloride(0.153 g (93.2 uL), 1 mmol), and the resulting suspension stirred at 0°C. for 3 hours. Tributylamine pyrophosphate (0.228 g) was added and thesuspension stirred at room temperature for 3 hours. The reaction wasquenched with 1.0 M aqueous triethylamine bicarbonate and the mixtureextracted with methylene chloride to remove trimethyl phosphate. Theaqueous solution was subjected to HPLC as in Example 3A above.Conversion of uridine to P¹,P⁴-di(uridine 5′-tetraphosphate) asquantitated by absorbance of the latter at 263 nm was 6.83%.

EXAMPLE 6 Method for the Production of Diuridine Tetraphosphate UsingUridine 5′-Monophosphate and Pyrophosphoryl Chloride

Uridine 5′-monophosphate (UMP) (64.8 mg, 0.2 mmol) was dissolved in drypyridine (1 mL) and stirred in ice during the addition of pyrophosphorylchloride (13.9 uL (25 mg), 0.1 mmol). The solution became cloudy almostimmediately, then a copious semicrystalline white precipitate formedwhich became a gummy mass within 1-2 minutes. The mixture was stored atroom temperature overnight, the quenched with water and subjected toHPLC as in Example 3A above. Yield of P¹,P⁴-di(uridine5′)-tetraphosphate as quantitated by its absorbance at 263 nm was 15.8%.A substantial amount of P′,P³-di(uridine 5′)-triphosphate (25.4%) wasobtained as the major by-product.

EXAMPLE 7 Aqueous Stability and Solubility of P¹,P⁴-di(uridine5′-tetraphosphate), Tetrasodium Salt

The solubility of P¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium saltin water was determined by adding portions of solid to a known volume ofdeionized water until the solution became turbid. The maximum solubilityin water was thus determined to be ca. 900 mg/mL. Stability studies ofthe solid or aqueous solutions incubated at low (5° C.) and elevatedtemperatures (40° C.) showed that less than 1.5% degradation occurs overa three month period as determined by HPLC analysis. The tetrasodiumsalt of P¹,P⁴-di(uridine 5′-tetraphosphate) was thus determined to havean excellent solubility and stability profile suitable forpharmaceutical applications.

EXAMPLE 8 Toxicity of P¹,P⁴-di(uridine 5′-tetraphosphate), TetrasodiumSalt in Animals

The nonclinical toxicologic profile of P¹,P⁴-di(uridine5′-tetraphosphate), tetrasodium salt has been evaluated in a battery ofgenetic toxicology assays that include the bacterial reverse mutationassay, the in vitro mammalian cytogenetic test, the in vitro mammaliancell gene mutation test, and the micronucleus cytogenetic assay in mice.A study in rabbits examined local ocular tolerance and subchronic oculartoxicity after multiple daily administrations over a six-week period. Inaddition, P¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium salt has alsobeen tested in two single-dose acute inhalation toxicity studies in ratand dog, and one single-dose acute intravenous toxicity study in dogs.

The results of these studies show that P¹,P⁴-di(uridine5′-tetraphosphate), tetrasodium salt is nongenotoxic in a battery ofgenetic toxicology assays. No adverse findings were seen in the oculartoxicology studies. A low degree of acute toxicity was seen in singledose inhalation (rats, dogs) and intravenous (dogs) toxicity studies.P¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium salt was thereforedetermined to have an excellent toxicology profile with a wide safetymargin for dosing in humans.

EXAMPLE 9 Safety and Efficacy of P¹,P⁴-di(uridine 5′-tetraphosphate),Tetrasodium Salt in Normal Human Volunteers

P¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium salt was evaluated in aPhase I, double-blind, placebo-controlled, escalating dose, safety andtolerability study in 75 normal healthy male volunteers. Fortynon-smokers and 35 smokers were evaluated in 5 dosing cohorts of 16volunteers, comprised of 12 receiving a single aerosolized dose ofP¹,P⁴-di(uridine 5′-tetraphosphate), tetrasodium salt (20-400 mg) and 4receiving placebo (normal saline). No serious adverse events werereported. There were no significant changes in FEV₁, FVC, MMEF, clinicallaboratory, 12-lead ECG, or urinalysis results in either the placebo oractive drug groups. In smokers, P¹,P⁴-di(uridine 5′-tetraphosphate),tetrasodium salt produced a 2-fold to 7-fold dose-dependent increase inthe weight of sputum expectorated within 5 minutes of dosing, andstimulation of sputum expectoration was sustained over the next hour ofsputum collection. The effect of P¹,P⁴-di(uridine 5′-tetraphosphate),tetrasodium salt to induce the expectoration of sputum in non-smokerswas also observed. In conclusion, P¹,P⁴-di(uridine 5′-tetraphosphate),tetrasodium salt is safe and well-tolerated in normal male subjects andis effective in stimulating the expectoration of sputum when compared toplacebo.

What is claimed is:
 1. P¹,P⁴-di(uridine 5′)-tetraphosphate, tetrasodiumsalt.